Vivoryon Therapeutics N.v. · EURONEXT:VVY
Vivoryon Therapeutics — Probiodrug — FY2014 Earnings Presentation
22 slides from Vivoryon Therapeutics's earnings presentation, Mar 31, 2015
Slide 1: The 2014 financial year: Full year results
The 2014 financial year Full year results Halle (Saale), 31 March 2015 Konrad Glund Hendrik Liebers Inge Lues CEO CFO CDO 1
Slide 2: Important notice and disclaimer
Important notice and disclaimer This Presentation has been prepared and issued by Probiodrug AG (the “Company”) and has not been independently verified by any third party. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any proj
Slide 3: Content
Content 1. Corporate introduction 2. Results 2014 3. Outlook 4. Q & A 3
Slide 4: Investment highlights
Investment highlights Alzheimer’s Disease (“AD”) is a devastating neurological disease affecting Alzheimer’s Disease: major over 35 million people world-wide* 1 burden, no cure No cure or long-term beneficial treatment available No new drugs approved since 2007** Developing a differentiated
Slide 5: Strategy & business model
Strategy & business model Focus key capabilities Pre-clinical Phase 1 Phase 2 Phase 3 Market Clinical proof of concept Potential starting point for partnering discussions Strategic objectives Continue to develop PQ912 through Phase 2a clinical trials and beyond Advance development of PBD-C06 and
Slide 6: Management team
Management team Management team Biography Konrad Glund, Co-founder of Probiodrug, CEO since 2006 PhD, CEO Led development of DP 4 inhibitors, transactions with Merck, Novartis, OSI and Ferring Co-founder COO & VP business development OSI (Prosidion) in 2004-2006 Chairman of the > 10 deals at
Slide 7: Alzheimer's Disease: growing burden, no cure
Alzheimer's Disease: growing burden, no cure Worldwide patient population will triple in Alzheimer's Disease introduction* the next 30 years** Leading cause of dementia, ultimately CAGR leading to death +3% 115 Large burden on families 35 Growing cost for society Available treatments margina
Slide 8: Original Abeta approach
Original Abeta approach Probiodrug targets toxic structures in Alzheimer's Disease Considerations Most new drug Most new drugs have focused on Abeta formation or Abeta/plaque clearance treatments have targeted Abeta or plaques Therapies have focused on: 1. Reduction of Abeta formation 2. Clearan
Slide 9: Probiodrug's differentiated approach
Probiodrug’s differentiated approach Probiodrug targets toxic structures in Alzheimer's Disease Considerations Probiodrug and others Most new drugs have focused on Abeta formation or Abeta/plaque clearance have progressed insights on Abeta and its role in AD Abeta has a physiological function
Slide 10: Focused proprietary pipeline
Focused proprietary pipeline Pre- Product Phase 1 Phase 2 clinical PQ912 Small molecule QC inhibitor First patient enrolled March 2015 PBD-C06 pGlu-Abeta specific monoclonal antibody PQ1565 Small molecule QC inhibitor Clinical proof of concept 10
Slide 11: Content
Content 1. Corporate introduction 2. Results 2014 3. Outlook 4. Q & A 11
Slide 12: Highlights
Highlights 2014 Successful initial public offering (IPO) on Euronext Amsterdam raising EUR 23,2 million Cash and cash equivalents of EUR 20,9 million as of 31 December 2014 Net loss of EUR 11.4 million compared with EUR 9.8 million in 2013, in line with expectations Lead product for treating
Slide 13: Key financial figures
Key financial figures 2014 2013 2013 2012 2011 In EUR k (unconsolidated*) (consolidated) Earnings, Financial and Net Assets Position Revenues 0 0 0 6 21 Operating profit/loss -11,267 -9,701 -9,651 -10,558 -14,269 Net loss for the period -11,437 -9,807 -9,929 -18,720 -16,307 Equity (end of the year)
Slide 14: Details of the Financial Results (according to IFRS)
Details of the Financial Results (according to IFRS) Net loss net loss Net loss in line with expectations Operating loss primarily driven by R&D expenses Increase in operating expenses reflects operating loss EUR 11,267 k primarily IPO preparation costs and post-listing financial loss EUR 170
Slide 15: Operational Review
Operational Review Pipeline Update PQ912 In 2014 prepared for a Phase 2a study (SAPHIR). In preceding Phase 1 study with healthy young and elderly volunteers was shown to be safe and well tolerated and revealed high QC-inhibition. First QC-inhibitor being tested in humans. SAPHIR is a random
Slide 16: Operational Review
Operational Review PBD-C06 Monoclonal antibody targeting pGlu-Abeta, currently in preclinical stage Successfully humanized and also de-immunized PQ1565 Second QC-inhibitor with attractive drug-like properties, currently in preclinical stage Regulatory toxicology studies in preparation, produ
Slide 17: The Probiodrug Share
The Probiodrug Share KEY FIGURES AS OF 31 DECEMBER 2014 SHAREHOLDERS ISIN: DE0007921835 WKN: 792183 Ticker Symbol: PBD Type of shares: Bearer shares Number of shares: 6,765,898 Stock exchange: Euronext Amsterdam Liquidity Provider: Kempen & Co. First trading day: 27 October 2014 IP
Slide 18: Content
Content 1. Corporate introduction 2. Results 2014 3. Outlook 4. Q & A 18
Slide 19: Outlook 2015
Outlook 2015 The mid-term focus of Probiodrug’s business activities can be summarised as follows: Further preclinical and clinical testing of the development candidate PQ912, in particular execution of the first patient study in a Phase 2a “SAPHIR” trial in 2015/2016 Securing further supporting
Slide 20: Anticipated news flow (selection)
Anticipated news flow (selection) PQ912 CTA submission for Phase 2 ✔ 2014 PQ912 First patient enrolled ✔ PQ912 Publication of complete Phase 1 results 2015 PBD-C06 Results in inflammatory part of AD pathology in animal model PQ912 Assessment of potential in Down syndrome PBD-C06 start of
Slide 21: Financial Calendar
Financial Calendar 13 May 2015 Interim Management Statement Q1 2015 10 June 2015 Annual General Meeting of Shareholders in Berlin 27 August 2015 Interim Report, half year results 2015 19 November 2015 Interim Management Statement Q3 2015 21
Slide 22: Content
Content 1. Corporate introduction 2. Results 2014 3. Outlook 4. Q & A 22